- call +1-201-465-4211
- email sales@mrinsights.biz
PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).
They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.
PARP (Poly ADP-Ribose Polymerase) Inhibitor first approval in United States in 2014. And in the last several years, global market (value) of PARP (Poly ADP-Ribose Polymerase) Inhibitor developed rapidly, with an average growth rate of 133.8% during 2015 to 2018.
The classification of PARP (Poly ADP-Ribose Polymerase) Inhibitor includes Lynparza, Zejula, Rubraca, Talzenna and other. Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment to potentially exploit DNA damage response (DDR) pathway deficiencies, such as BRCA mutations, to preferentially kill cancer cells.
According to this study, over the next five years the PARP (Poly ADP-Ribose Polymerase) Inhibitor market will register a 34.0% CAGR in terms of revenue, the global market size will reach US$ 5097.7 million by 2024, from US$ 1178.8 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in PARP (Poly ADP-Ribose Polymerase) Inhibitor business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of PARP (Poly ADP-Ribose Polymerase) Inhibitor market by product type, application, key manufacturers and key regions and countries.
This study considers the PARP (Poly ADP-Ribose Polymerase) Inhibitor value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Lynparza
Zejula
Rubraca
Talzenna
Other
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Ovarian Cancer
Breast Cancer
Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
AstraZeneca
Tesaro
Merck & Co
Clovis Oncology
Pfizer
...
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global PARP (Poly ADP-Ribose Polymerase) Inhibitor consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of PARP (Poly ADP-Ribose Polymerase) Inhibitor market by identifying its various subsegments.
Focuses on the key global PARP (Poly ADP-Ribose Polymerase) Inhibitor manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the PARP (Poly ADP-Ribose Polymerase) Inhibitor with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of PARP (Poly ADP-Ribose Polymerase) Inhibitor submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
2019-2024 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Market Report
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption 2014-2024
2.1.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption CAGR by Region
2.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Type
2.2.1 Lynparza
2.2.2 Zejula
2.2.3 Rubraca
2.2.4 Talzenna
2.2.5 Other
2.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Type
2.3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Market Share by Type (2014-2019)
2.3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Type (2014-2019)
2.3.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sale Price by Type (2014-2019)
2.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Application
2.4.1 Ovarian Cancer
2.4.2 Breast Cancer
2.4.3 Other
2.5 PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Application
2.5.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Market Share by Application (2014-2019)
2.5.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Value and Market Share by Application (2014-2019)
2.5.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sale Price by Application (2014-2019)
3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor by Manufacturers
3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Manufacturers
3.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Manufacturers (2017-2019)
3.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Manufacturers (2017-2019)
3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Manufacturers
3.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Manufacturers (2017-2019)
3.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Manufacturers (2017-2019)
3.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sale Price by Manufacturers
3.4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturing Base Distribution, Sales Area, Product Types by Manufacturers
3.4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturing Base Distribution and Sales Area by Manufacturers
3.4.2 Players PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 PARP (Poly ADP-Ribose Polymerase) Inhibitor by Regions
4.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor by Regions
4.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Regions
4.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Value by Regions
4.2 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Growth
4.3 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Growth
4.4 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Growth
4.5 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Growth
5 Americas
5.1 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Countries
5.1.1 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Countries (2014-2019)
5.1.2 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Value by Countries (2014-2019)
5.2 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Type
5.3 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Countries
6.1.1 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Countries (2014-2019)
6.1.2 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Value by Countries (2014-2019)
6.2 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Type
6.3 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries
7 Europe
7.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor by Countries
7.1.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Countries (2014-2019)
7.1.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Value by Countries (2014-2019)
7.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Type
7.3 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor by Countries
8.1.1 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Countries (2014-2019)
8.1.2 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Value by Countries (2014-2019)
8.2 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Type
8.3 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors
10.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Customer
11 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast
11.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Forecast (2019-2024)
11.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecast by Regions
11.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecast by Regions (2019-2024)
11.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Value Forecast by Regions (2019-2024)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecast by Type
11.8 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecast by Application
12 Key Players Analysis
12.1 AstraZeneca
12.1.1 Company Details
12.1.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Offered
12.1.3 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2017-2019)
12.1.4 Main Business Overview
12.1.5 AstraZeneca News
12.2 Tesaro
12.2.1 Company Details
12.2.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Offered
12.2.3 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2017-2019)
12.2.4 Main Business Overview
12.2.5 Tesaro News
12.3 Merck & Co
12.3.1 Company Details
12.3.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Offered
12.3.3 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2017-2019)
12.3.4 Main Business Overview
12.3.5 Merck & Co News
12.4 Clovis Oncology
12.4.1 Company Details
12.4.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Offered
12.4.3 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2017-2019)
12.4.4 Main Business Overview
12.4.5 Clovis Oncology News
12.5 Pfizer
12.5.1 Company Details
12.5.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Offered
12.5.3 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2017-2019)
12.5.4 Main Business Overview
12.5.5 Pfizer News
...
13 Research Findings and Conclusion
List of Tables and Figures
Figure Picture of PARP (Poly ADP-Ribose Polymerase) Inhibitor
Table Product Specifications of PARP (Poly ADP-Ribose Polymerase) Inhibitor
Figure PARP (Poly ADP-
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
